Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2026,
Artgen Biotech PJSC paid₽0 Mil more to buy back shares than it received from issuing new shares.
It received₽0 Mil from issuing more debt.
It paid₽0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spent₽24 Mil paying cash dividends to shareholders.
It spent₽44 Mil on other financial activities.
In all, Artgen Biotech PJSCspent₽68 Mil on financial activities for the
six
months ended in Jun. 2026.
Artgen Biotech PJSC (MIC:ABIO) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Artgen Biotech PJSC's issuance of stock for the
six
months ended in Jun. 2026 was ₽0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Artgen Biotech PJSC's repurchase of stock for the
six
months ended in Jun. 2026 was ₽-0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Artgen Biotech PJSC's net issuance of debt for the
six
months ended in Jun. 2026 was ₽0 Mil.
Artgen Biotech PJSC received₽0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Artgen Biotech PJSC's net issuance of preferred for the
six
months ended in Jun. 2026 was ₽ Mil.
Artgen Biotech PJSC paid₽0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Artgen Biotech PJSC's cash flow for dividends for the
six
months ended in Jun. 2026 was ₽-24 Mil.
Artgen Biotech PJSC spent₽24 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Artgen Biotech PJSC's other financing for the
six
months ended in Jun. 2026 was ₽-44 Mil.
Artgen Biotech PJSC spent₽44 Mil on other financial activities.
Artgen Biotech PJSC Cash Flow from Financing Related Terms
Artgen Biotech PJSC Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Artgen Biotech PJSC's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artgen Biotech PJSC Cash Flow from Financing Chart
Artgen Biotech PJSC Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Artgen Biotech PJSC's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₽203 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of ₽203 Mil mean?
Artgen Biotech PJSC (MIC:ABIO) has a Cash Flow from Financing of ₽203 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Cash Flow from Financing too high?
Artgen Biotech PJSC's current Cash Flow from Financing is ₽203 Mil. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Cash Flow from Financing compare to VRTX and REGN?
Artgen Biotech PJSC's Cash Flow from Financing of ₽203 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current Cash Flow from Financing is ₽203 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Cash Flow from Financing of ₽203 Mil. The current Cash Flow from Financing is ₽203 Mil. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Cash Flow from Financing is ₽203 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score
Get the complete analysis for MIC:ABIO
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIC:ABIO has been successfully added to your 
